125962-59-6

Basic information

• Product Name: 8-(4-BROMOPHENYL)-1,4-DIOXASPRIO[4,5]DECAN-8-OL
• Synonyms: 8-(4-BROMOPHENYL)-1,4-DIOXASPRIO[4,5]DECAN-8-OL;8-(4-bromophenyl)-1,4-Dioxaspiro[4.5]decan-8-ol
• CAS NO: 125962-59-6
• Molecular Formula: C₁₄H₁₇BrO₃
• Molecular Weight: 313.19
• Mol File: 125962-59-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 423.4°Cat760mmHg
• Flash Point: 209.9°C
• Appearance: /
• Density: 1.5g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.615
• PKA: 14.09±0.20(Predicted)
• CAS DataBase Reference: 8-(4-BROMOPHENYL)-1,4-DIOXASPRIO[4,5]DECAN-8-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 8-(4-BROMOPHENYL)-1,4-DIOXASPRIO[4,5]DECAN-8-OL(125962-59-6)
• EPA Substance Registry System: 8-(4-BROMOPHENYL)-1,4-DIOXASPRIO[4,5]DECAN-8-OL(125962-59-6)

Safety Data

• Hazardous Substances Data: 125962-59-6(Hazardous Substances Data)

Usage

General Description

8-(4-BROMOPHENYL)-1,4-DIOXASPRIO[4,5]DECAN-8-OL is a chemical compound that belongs to the class of 1,4-dioxaspiro[4,5]decane compounds. It consists of a dioxaspirodecane backbone with a bromophenyl group attached to the eighth carbon and a hydroxyl group attached to the same carbon. 8-(4-BROMOPHENYL)-1,4-DIOXASPRIO[4,5]DECAN-8-OL may have potential applications in pharmaceutical research, particularly in the development of new drug candidates, as well as in the field of organic chemistry for the synthesis of other complex molecules. Its unique structure and properties make it an interesting target for further study and potential use in various scientific and industrial applications.

InChI:InChI=1/C14H17BrO3/c15-12-3-1-11(2-4-12)13(16)5-7-14(8-6-13)17-9-10-18-14/h1-4,16H,5-10H2

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 106-37-6 1.4-dibromobenzene 
• 589-87-7 1,4-bromoiodobenzene 

Downstream Products

• 1477524-02-9 2-(4-(4'-((5-(tert-butyl)-1,3,4-oxadiazol-2-yl)amino)-[1,1'-biphenyl]-4-yl)-7-oxabicyclo[2.2.1]heptan-1-yl)acetic acid 
• 1477524-74-5 methyl 2-(4-(4'-((5-(tert-butyl)-1,3,4-oxadiazol-2-yl)amino)-[1,1'-biphenyl]-4-yl)-7-oxabicyclo[2.2.1]heptan-1-yl)acetate 
• 1477524-73-4 methyl 2-(4-(4-bromophenyl)-7-oxabicyclo[2.2.1]heptan-1-yl)acetate 
• 1477524-72-3 methyl 2-(4-(4-bromophenyl)-4-hydroxycyclohexylidene)acetate 
• 1477524-71-2 4-(4-bromophenyl)-4-hydroxycyclohexan-1-one 
• 919100-06-4 8-(4-bromophenyl)-8-[(4-trifluoromethyl)phenylthiol]-1,4-dioxa-spiro[4.5]decane 
• 125962-60-9 8-(4-bromophenyl)-1,4-dioxaspiro[4.5]dec-7-ene 

Relevant articles and documents

Synthesis of Fluorenes and Dibenzo[ g,p]chrysenes through an Oxidative Cascade

We have developed robust, operationally simple syntheses of fluorenes and of dibenzo[g,p]chrysenes through oxidative cascade processes. These structures that are commonly encountered in optoelectronic materials, dyes, and pharmaceutical products are acces

LIQUID CRYSTAL COMPOUND HAVING HALOGENATED ALKYL, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT

PROBLEM TO BE SOLVED: To provide a liquid crystal compound satisfying at least one of demands for physical properties such as high stability to heat or light, high clearing point (or high maximum temperature), low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large dielectric anisotropy, suitable elastic modulus, and excellent compatibility with other liquid crystal compounds, a liquid crystal composition comprising the above compound, and a liquid crystal display element including the composition. SOLUTION: The compound is represented by formula (1). In formula (1), R1X represents an alkyl substituted with a halogen; ring A1, ring A2, ring A3, ring A4 and ring A5 represent a 1,4-phenylene or the like; Z1, Z2, Z3 and Z4 represent a single bond, -COO-, or the like; X1 represents fluorine, -CF3, or the like; L1 and L2 represent fluorine or the like; and a, b, c and d represent 0 or 1. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS

The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.